Abstract
The granzyme B-induced cell death has been traditionally viewed as a primary mechanism that is used by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to eliminate harmful target cells including allogeneic, virally infected and tumour cells Granzyme B (GrB) is the most abundant senne protease which is stored in secretory granules of CTLs and NK cells After recognition of the target cell, the engaged CTLs and NK cells vectonally secrete GrB along with other granule proteins including perform into the immunological synapse From this submicroscopic intercellular cleft GrB translocates into the cytoplasm of the target cell Although several models have been proposed to explain the GrB delivery mechanism, conclusive understanding of this process remains still elusive Once in the cytoplasm, GrB cleaves and activates or inactivates, multiple protein substrates, resulting eventually into apoptotic demise of the target cell This review is focused on the gene structure and expression of GrB, its biosynthesis and activation, delivery mechanisms into the target cell cytoplasm, direct proteolytic involvement in activation of several pro-apoptotic pathways, and on regulation of its activity in cancer cells Moreover, emphasis is given to the GrB-mediated anticancer effects and future clinical applications of the GrB-based and tumour-targeted recombinant fusion constructs